Capmatinib price in the Philippines (2026)

There is no fixed public retail price for capmatinib in the Philippines in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 1,500–BDT 1,500 (US$12.21–US$12.21) per unit, about PHP 765.57–PHP 765.57 in PHP per unit and PHP 22,967–PHP 22,967 per 30-unit month, before freight, customs duty and distributor margin.

Yes, but only through the rules of the Philippine Food and Drug Administration (FDA Philippines): The Philippines has universal healthcare (PhilHealth) and a government Maximum Drug Retail Price list, but specialty oncology drugs are mostly out-of-pocket. Bangladeshi and Indian generics are imported through licensed distributors or via FDA Philippines compassionate special permit for personal use. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

We cannot confirm the registration status of every individual generic brand in the Philippines. Philippine Food and Drug Administration (FDA Philippines) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.

Philippines: not confirmed. No public FDA Philippines approval record found in this search